We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+11.68%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$19.1B
AUM Growth
+$1.76B
Cap. Flow
+$154M
Cap. Flow %
0.81%
Top 10 Hldgs %
32.12%
Holding
703
New
28
Increased
257
Reduced
281
Closed
39

Top Buys

Rank Stock Value
1
NU icon
Nu Holdings
NU
+$60.7M
2
JNJ icon
Johnson & Johnson
JNJ
+$58.3M
3
SCHW
Charles Schwab
SCHW
+$54M
4
ABBV icon
AbbVie
ABBV
+$52.9M
5
PANW icon
Palo Alto Networks
PANW
+$42.9M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$92.7M
2
EMR icon
Emerson Electric
EMR
+$57.2M
3
MELI icon
Mercado Libre
MELI
+$48.9M
4
AVGO icon
Broadcom
AVGO
+$38.9M
5
MU icon
Micron Technology
MU
+$37.7M

Sector Composition

Rank Sector Weight
1 Technology 36.63%
2 Healthcare 23.08%
3 Financials 11.48%
4 Consumer Discretionary 7.78%
5 Communication Services 6.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RNAM
176
DELISTED
Avidity Biosciences
RNAM
$21.3M 0.11%
487,917
+45,144
+10% +$1.82M
SYY icon
177
Sysco
SYY
$41.3B
$20.6M 0.11%
249,841
+76,160
+44% +$6.09M
MSCI icon
178
MSCI
MSCI
$41.6B
$20.6M 0.11%
36,221
+30,875
+578% +$17.5M
BRO icon
179
Brown & Brown
BRO
$24.8B
$20.4M 0.11%
217,538
-12,855
-6% -$1.25M
FISV
180
Fiserv Inc
FISV
$28.7B
$20.3M 0.11%
157,394
-58,043
-27% -$8.32M
MTB icon
181
M&T Bank
MTB
$36.4B
$20.1M 0.11%
101,459
+84,462
+497% +$16.6M
VNET
182
VNET Group
VNET
$1.9B
$19.9M 0.1%
+1,922,000
New +$16.2M
IBM icon
183
IBM
IBM
$205B
$19.6M 0.1%
69,355
-4,062
-6% -$1.06M
CELC icon
184
Celcuity
CELC
$3.88B
$19.3M 0.1%
390,924
+127,348
+48% +$5.1M
CHE icon
185
Chemed
CHE
$6.89B
$19.3M 0.1%
43,056
-12,553
-23% -$5.68M
HLT icon
186
Hilton Worldwide
HLT
$72.8B
$19.2M 0.1%
73,823
+7,441
+11% +$2.01M
FCX icon
187
Freeport-McMoran
FCX
$87B
$19.1M 0.1%
486,128
+43,163
+10% +$1.87M
TMUS icon
188
T-Mobile US
TMUS
$199B
$19M 0.1%
79,166
-42,000
-35% -$10.2M
EXAS
189
DELISTED
Exact Sciences
EXAS
$18.9M 0.1%
345,399
VRDN icon
190
Viridian Therapeutics
VRDN
$2.13B
$18.6M 0.1%
860,232
-2,041
-0.2% -$36.8K
TWLO icon
191
Twilio
TWLO
$28.8B
$18.1M 0.09%
180,787
+4,334
+2% +$488K
VZ icon
192
Verizon
VZ
$204B
$18.1M 0.09%
410,994
-11,589
-3% -$502K
EME icon
193
Emcor
EME
$31.2B
$17.8M 0.09%
27,443
+130
+0.5% +$78.9K
TERN
194
DELISTED
Terns Pharmaceuticals
TERN
$17.8M 0.09%
2,368,235
INTU icon
195
Intuit
INTU
$87.2B
$17.7M 0.09%
25,974
-209
-0.8% -$151K
BVN icon
196
Compañía de Minas Buenaventura
BVN
$7.73B
$17.6M 0.09%
724,000
+94,000
+15% +$1.76M
HIMS icon
197
Hims & Hers Health
HIMS
$6.45B
$17.4M 0.09%
306,273
+217,493
+245% +$11.1M
KD icon
198
Kyndryl
KD
$2.91B
$17.2M 0.09%
572,769
+434,245
+313% +$14.9M
MAR icon
199
Marriott International
MAR
$100B
$17.1M 0.09%
65,686
TXN icon
200
Texas Instruments
TXN
$253B
$17M 0.09%
92,676
-826
-0.9% -$161K

Similar funds

Candriam SCA's Q3 2025 Portfolio in Review

As of Q3 2025, Candriam SCA held 703 positions worth $19.1B, up 10% from $17.3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Candriam SCA's Q3 2025 filing shows 28 new, 257 increased, 281 reduced and 39 closed positions. Its largest new stake was Banco Macro: 322,600 shares worth $13.6M. The largest sale was NVIDIA, an estimated $92.7M.

By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 36% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q3 2025 buy was Banco Macro: 322,600 shares worth $13.6M.
  • Candriam SCA added most to Nu Holdings in Q3 2025, an estimated $60.7M increase.
  • Candriam SCA's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $92.7M.
  • Candriam SCA fully exited Verona Pharma in Q3 2025, selling an estimated $20.5M.
  • Candriam SCA's ten largest holdings make up 32% of its $19.1B portfolio in Q3 2025.
  • Candriam SCA opened 28 new positions and closed 39 in Q3 2025.
  • Candriam SCA's portfolio value rose 10% quarter-over-quarter to $19.1B.

Based on Candriam SCA's 13F filing for Q3 2025, filed 6 Nov 2025.